


B7H4 ECD-TF mRNA-LNP

Ready-to-use lipid nanoparticles



Order Information

Catalog# PM-LNP-0103 Size 200uL

Description

B7H4 (B7 Homolog 4), also known as VTCN1 (V-set domain containing T cell activation inhibitor 1), is a type I membrane expressed by antigen presenting cells. Binding of B7H4 to receptors on T cells inhibits T cell activation, proliferation and function. In solid tumors, B7H4 expression on tumor-associated macrophages is thought to inhibit adjacent T cell function, reducing antitumor immunity. Studies have also shown that high levels of B7H4 are associated with tumor progression. B7H4 is comprised of 282 amino acids and its GenPept accession number is NP_078902. ProMab's PM-LNP-0103 nanoparticles contain an mRNA encoding the extracellular domain of B7H4 and a C-terminal TF tag (15 amino acids). The nanoparticles are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery in vitro and in vivo.

Composition

mRNA-LNPs are suspended in PBS (-Ca, -Mg) (pH: 7.0-7.4).

Storage

Product is delivered on wet ice. Store at 4°C for up to 3 months.

Handling

Upon receipt, centrifuge the vial for a few seconds to ensure the contents are located at the bottom of the vial. Vortex mixing or prolonged centrifugation may rupture the nanoparticles. Store the vial of nanoparticles in the refrigerator and keep on ice when in use. Do not allow the nanoparticles to warm to room temperature. mRNA-LNP suspensions should only be handled with certified RNase-free reagents and consumables. The use of filtered pipette tips is highly recommended.

B7H4 ECD-TF mRNA-LNP

Ready-to-use lipid nanoparticles

Safety & Research Disclosure

All ProMab mRNA lipid nanoparticle products are for in vitro research use only. Products are not FDA approved for human use.

Protocol for Transfecting Suspension Cells

Suspend 0.5 - 1 million cells in 1 ml of culture medium. Ensure the cells are healthy and well-dispersed, as cell clumping may reduce transfection efficiency. Disperse the nanoparticle suspension by gently pipetting up and down several times, then slowly add 20-40 μ l to the cells, dropwise. Gently mix the cells and incubate them overnight in a culture incubator. The next day, and every day thereafter, check the culture for expression of the protein encoded by the mRNA-LNP. Cell-bound proteins can be detected by flow cytometry or western blotting using the transfected cells, whereas secreted proteins can be detected by ELISA, western blotting or flow cytometry (on a target cell line) using the medium collected from the transfected cells.

B7H4 ECD-TF Expression in HEK293S Cells Treated with PM-LNP-0103




Figure 1. Western Blot. Medium collected from PM-LNP-0103 nanoparticle-treated HEK293S cells contains the TF-tagged extracellular domain of B7H4, detected with an anti-TF antibody.

Products and Services

- Monoclonal Antibody
- Bispecific Antibody
- mRNA-LNP
- Hybridoma Sequencing
- CAR-T/NK
- Stable Cell Line

B7H4 ECD-TF mRNA-LNP

Ready-to-use lipid nanoparticles



Products and Services

- Monoclonal Antibody
- Bispecific Antibody
- mRNA-LNP
- Hybridoma Sequencing
- CAR-T/NK
- Stable Cell Line

B7H4 ECD-TF Secretion from HEK293S Cells Treated with PM-LNP-0103




Figure 2. Flow Cytometry. PM-LNP-0103 nanoparticle-treated HEK293S cells express the TF-tagged extracellular domain of B7H4, detected with an anti-TF antibody.